Migraine Trial, Recruiting NCT06938178 Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT06938178
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who have been diagnosed with high-frequency episodic migraine or chronic migraine, meaning they experience between 8 and 14 migraine days per month, based on recognised international headache diagnostic guidelines.
  • People whose migraine treatment has been stable and unchanged for at least 3 months before starting the mindfulness part of the study (if a treatment change happens at the screening visit, a 3-month waiting period applies before the mindfulness treatment begins).

Who may not be able to join:

  • People who have a history of, or have been assessed by a doctor as having, a psychiatric condition involving psychosis.
  • People who are currently pregnant.
  • People who have a secondary headache condition — meaning a headache disorder caused by another underlying condition, such as idiopathic intracranial hypertension (a condition involving raised pressure around the brain) (confirm with trial site if unsure whether a condition qualifies).
  • People who have gone through a detoxification programme for overuse of pain or headache relief medications two or more times in the past two years.
  • People who have previously received any form of mindfulness-based treatment or meditation therapy.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paola Lanteri, MD, Fondazione IRCCS Istituto Neurologico Carlo Besta

Phone: 02.2394.2538

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Registry
ClinicalTrials.gov
Start date
23 April 2024
Est. completion
1 June 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Correlation between neurophysiological indicators and clinical outcome

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov